Anti-chalmydial antibody as a predictive test for tubal factor infertility
نویسندگان
چکیده
منابع مشابه
The Role of Chlamydia trachomatis IgG Antibody Testing in Predicting Tubal Factor Infertility in Northern Iran
Background The purpose of this study was to investigate the role of Chlamydia serology as a screening test for tubal infertility and to compare the results with hysterosalpingography (HSG) and laparoscopic findings. MaterialsAndMethods This was a cross-sectional study undertaken on 110 infertile women treated in the IVF Ward, at Emam Khomeini Hospital, Sari, Iran who underwent laparoscopy and H...
متن کاملTubal telocytes: factor infertility reason?
Infertility is actually widespread pathological condition, which affected one in every four couples in developing countries. Approximately one third of all cases are connected with tubal factor infertility, o en accompanies by endometriosis, acute salpingitis, urogenital infections etc. The newly identified telocytes (TCs) have multiple potential bio-functions and might participate in the ferti...
متن کاملFluoroscopic tubal recanalization in tubal factor related infertility.
Infertility is defined as the inability to conceive after 1 year of unprotected intercourse, a definition that is based on a monthly fecundity rate of 15 to 25%. Approximately 10 to 20% of couples may experience problems conceiving, and infertility can result from a wide variety of etiologies. Female factors account for 40% of infertility.1 When investigating infertility, evaluation of both the...
متن کاملInfections and infertility due to tubal factor
Tubal factors are most important causes of infertility and are attributed to several etiologies. It seems that infections cause 10% to 70% of tubal factors and are strongly depended on patients age, numbers of infections and geogarphical and regional epidemiology. All types of tubal inflamations can impair fertility such as: acute salpingitis, tubo–ovarian abscess formation, asympothomatic invo...
متن کاملAbsolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy.
Over recent years, anti-CD20 monoclonal antibodies (Mab) have become available for the treatment of B-cell non-Hodgkin’s lymphoma (NHL). Despite a relatively high response rate, a few patients appear to remain resistant to treatment. In order to identify patients in whom rituximab could be beneficial, we evaluated the influence of various clinical and laboratory parameters on response to immuno...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Al-Azhar Medical Journal
سال: 2020
ISSN: 1110-0400
DOI: 10.21608/amj.2020.67131